Health
Establishment Labs secures FDA approval for expanded Motiva implants
Establishment Labs Holdings (NASDAQ:ESTA) secured U.S. Food and Drug Administration approval for an expanded range of Motiva SmoothSilk Round and Ergonomix breast implants.
Liezl Gambe
Finance JournalistFinance journalist at Grafa with years of experience covering Asia-Pacific financial markets at S&P Global, Mortgage Ezy, and GMA Network.
Contact
Contact editorial teamArticles by Liezl Gambe
Transport and logistics
C.H. Robinson to acquire RXO for $5.8 billion
C.H. Robinson (NASDAQ:CHRW) agreed to acquire RXO (NYSE:RXO) in a $5.8 billion stock-and-cash transaction.
Health
Vaxcyte VAX-31 meets all primary endpoints in Phase 3 trial
Vaxcyte (NASDAQ:PCVX) reported that VAX-31 met all prespecified primary endpoints in its OPUS-1 Phase 3 trial.
Technology
PTC surges on $22.6 billion Schneider buyout deal
PTC (NASDAQ:PTC) shares surged 34.6% to $193.80 in premarket trading after agreeing to a buyout.
Technology
Foxconn reports 47% jump in third-quarter revenue
Taiwan's Foxconn, the world's largest contract electronics maker and Nvidia's (NASDAQ:NVDA) biggest server manufacturer, reported a 47% year-over-year jump in third-quarter revenue.
Financial
Clime Capital receives qualified audit on FY26 results
Clime Capital (ASX:CAM) reported a $13.4 million pre-tax profit for FY26 while receiving a qualified audit opinion regarding unlisted unit trust holdings.
Financial
Etherstack plans capital reorganisation to enable future dividends
Etherstack (ASX:ESK) announced plans to reorganise its share premium account via a capital reduction to establish distributable reserves.
Cryptocurrency
OKXICE files for round-the-clock tokenised stocks
OKXICE LLC has notified the US Securities and Exchange Commission of plans for tokenised stock trading.
Mining
OD6 Metals raises $6.9M for fluorspar
OD6 Metals (ASX:OD6) has secured firm commitments to raise approximately $6.9 million before costs.
Health
Dimerix reaches four year patient clinical trial milestone
Dimerix (ASX:DXB) announced that its first patient completed a two-year open-label extension study, marking four continuous years of DMX-200 treatment.